Abstract
BackgroundHematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure—Quality of Care Index (QCI)—to appraise the quality of care in different populations.MethodsThe Global Burden of Disease data from 1990 to 2017 applied in our study. We performed a principal component analysis on several secondary indices from the major primary indices, including incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) to create the QCI, which provides an overall score of 0–100 of the quality of cancer care. We estimated the QCI for each age group on different scales and constructed the gender disparity ratio to evaluate the gender disparity of care in HMs.ResultsGlobally, while the overall age-standardized incidence rate of HMs increased from 1990 to 2017, the age-standardized DALYs and death rates decreased during the same period. Across countries, in 2017, Iceland (100), New Zealand (100), Australia (99.9), and China (99.3) had the highest QCI scores for non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, and leukemia. Conversely, Central African Republic (11.5 and 6.1), Eritrea (9.6), and Mongolia (5.4) had the lowest QCI scores for the mentioned malignancies respectively. Overall, the QCI score was positively associated with higher sociodemographic of nations, and was negatively associated with age advancing.ConclusionsThe QCI provides a robust metric to evaluate the quality of care that empowers policymakers on their responsibility to allocate the resources effectively. We found that there is an association between development status and QCI and gender equity, indicating that instant policy attention is demanded to improve health-care access.
Highlights
Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse sub‐ groups of neoplasms
All these are indirect assessors of quality of care; which are: (1) years of life lost (YLLs) to years lived with disability (YLDs) ratio (2) disability-adjusted life year to prevalence ratio (3) mortality to incidence ratio (MIR) (4) prevalence to incidence ratio
Hodgkin lymphoma Globally, there were 101,133 (95% uncertainty interval (UI) 87,968 to 118,746) incident cases of Hodgkin lymphoma in 2017, which indicates a 38.6% increase in incidence between 1990 and 2017
Summary
Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse sub‐ groups of neoplasms. Despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. we created a novel measure—Quality of Care Index (QCI)—to appraise the qual‐ ity of care in different populations. Hematologic malignancies (HMs) are a heterogeneous group of malignant disorders that are essential contributors in cancer global burden [1]. They are commonly classified by their four common subtypes: leukemia, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM) [2]. With regard to the increasing trend, more intensive attention should be paid to these patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
